We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug & Device Products
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Publications
    • Webinar Training Pass
    • eCFR and Guidances
    • Books
  • Clinical Products
  • Advertising
  • White Papers
  • Contact Us
  • About Us
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Patient Advocacy Group Seeks PTO Review of Wyeth's Tygacil Patent

Patient Advocacy Group Seeks PTO Review of Wyeth's Tygacil Patent

August 20, 2014

A patient advocacy group is using a recently created pathway for challenging generic drugs through the U.S. Patent and Trademark Office to contest the patent on Wyeth’s antibiotic Tygacil outside a Hatch-Waxman ANDA.

The Initiative for Responsibility in Drug Pricing filed what is known as an inter parties review challenge against Tygacil (tigecycline) on August 8 in front of the PTO’s Patent Trial and Appeal Board. The group argues in its petition that Tygacil’s ‘828 patent would have been obvious for other drugmakers to try and is therefore invalid.

Tygacil is already facing a separate patent review board challenge filed by generics maker Apotex, IRDP notes, a challenge due for oral arguments on January 23, 2015. A separate challenge is necessary in case the two parties settle outside of the review process and delay market entry of Apotex’s generic Tygacil, the group says in requesting that the PTO take up the second trial.

In its petition, IRDP touts the fact that it has no ties with any pharmaceutical company, giving it the ability to exclusively serve the public interest rather than the interests of negotiating parties. The group exists explicitly to give Americans more access to lower-cost generics by challenging and invalidating drug patents, the petition says. Outside challengers are important because generics companies will often settle litigation with the brand manufacturer rather than fully invalidate what IRDP calls “dubious patents,” the petition adds.

There are growing signs that other generics companies also are catching on to IPR challenges and two other forms of PTO review created by the 2011 America Invents Act. Such reviews are cheaper and faster than their Hatch-Waxman counterparts and may be friendlier to patent challengers.

There were means beyond ANDAs to challenge drug patents in the past, says Amir Naini, a lawyer with Russ August & Kabat who is representing IRDP. The AIA reviews simply represent the latest means for outside parties to challenge drug patents.

Wyeth parent Pfizer confirmed the challenge but declined to comment further. — Bryan Koenig

Originally appeared in Drug Industry Daily, the pharmaceutical industry’s number one source for regulatory news and information. Click here for more information.

Pharmaceuticals Commercial Operations

Upcoming Events

  • 13Jul

    FDA Ad and Promo Enforcement Trends: Past, Present and Future

  • 28Jul

    EU-MDR’s Growing Pains: Are You Current with the Latest Developments?

  • 28Jul

    Is Your Product a Drug or Device — and Does It Matter?: A Recent Appeals Court Decision Says It Does

  • 02Aug

    Medical Device Cybersecurity: Understand the Latest Developments

  • 03Aug

    Pharmaceutical Process Validation: Best Practices for Success

  • 10Aug

    Gene & Cell Therapy Regulation: Comparability and Other New Developments

Featured Products

  • FDA’s New Quality System Regulation: Transitioning from QSR to ISO 13485

    FDA’s New Quality System Regulation: Transitioning from QSR to ISO 13485

  • Selecting and Implementing Electronic Document Management Systems in the EU

    Selecting and Implementing Electronic Document Management Systems in the EU

Featured Stories

  • FDA Provides Update on GE Healthcare’s Recall of Its Carescape R860 Ventilators

  • Gilead Resubmits NDA for Lenacapavir Following Complete Response Letter

  • FDA Warns Baby Neck Floats Used in Water Therapy Can Cause Death or Injury

  • U.S. Government Inks $3.2 Billion Contract With Pfizer-BioNTech for Vaccine Booster Campaign

The Revised ICH E8: A Guide to New Clinical Trial Requirements

Learn More
  • Drug Products
    • Quality
    • Regulatory Affairs
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Device Products
    • Quality
    • Regulatory Affairs
    • QSR
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Clinical Products
    • Trial Design
    • Data Integrity
    • GCP
    • Inspections and Audits
    • Transparency
  • Privacy Policy
  • Do Not Sell My Personal Information
Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Toll free 888.838.5578

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing